AH5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) Vepacel®

Drugs

Volumn 72, Issue 11, 2012, Pages 1543-1557

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Influenza A virus infections; Influenza A virus vaccine H5N1

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE;

ARTICLE; DRUG TOLERABILITY; HEADACHE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H5N1); INJECTION SITE PAIN; NONHUMAN; VERO CELL; VIRION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG SCREENING; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H5N1; ORTHOMYXOVIRUS INFECTION; REVIEW;

INFLUENZA A VIRUS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED; VERO CELLS; VIRION;

EID: 84864226154     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209650-000000000-00000     Document Type: Article

References (26)

1. World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits [online]. Available from URL: http://whqlibdoc.who.int/publications/2011/ 9789241503082-eng.pdf [Accessed 2012 May 3]
2. World Health Organization. Pandemic influenza preparedness and response: a WHO guidance document [online].Available from URL: http://whqlibdoc.who.int/ publica tions/2009/9789241547680-eng.pdf [Accessed 2012 May 2]
3. Jennings LC, Monto AS, Chan PK, et al. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008 October; 8 (10): 650-8
4. Wright PF. Vaccine preparedness: are we ready for the next influenza pandemic? N Engl J Med 2008 12 Jun; 358 (24): 2540-3 (Pubitemid 351831355)
5. Amendola A, Ranghiero A, Zanetti A, et al. Is avian influenza virus A(H5N1) a real threat to human health? J Prev Med Hyg 2011 Sep; 52 (3): 107-10
6. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006 Jul 27; 442 (7101): 448-52 (Pubitemid 44264793)
7. Webster RG, Govorkova EA. H5N1 influenza: continuing evolution and spread. N Engl J Med 2006 Nov 23; 355 (21): 2174-7 (Pubitemid 44791158)
8. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines. Wkly Epidemiol Rec 2010 Oct 15; 85 (42): 418-24
9. Watanabe Y, Ibrahim MS, Suzuki Y, et al. The changing nature of avian influenza A virus (H5N1). Trends Microbiol 2012 January; 20 (1): 11-20
10. Barrett PN, Mundt W, Kistner O, et al. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009 May; 8 (5): 607-18
11. Steel J. New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges. BioDrugs 2011; 25 (5): 285-98
12. Kistner O, Barrett PN, Mundt W, et al. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998 May/Jun; 16 (9-10): 960-8 (Pubitemid 28276008)
13. Baxter Innovations GmbH. Vepacel suspension for injection: summary of product characteristics [online]. Availablefrom URL: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002089/WC500124223. pdf [Accessed 2012 May 2]
14. Kistner O, HowardMK, Spruth M, et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007 Aug 10; 25 (32): 6028-36 (Pubitemid 47077543)
15. Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 2008 May 1; 389 (5): 569-77 (Pubitemid 351874194)
16. Howard MK, Sabarth N, Savidis-Dacho H, et al. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 2011 Aug 18; 6 (8): e23791
17. Sabarth N, Howard MK, Savidis-Dacho H, et al. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 2010; 28 (3): 650-6
18. European Medicines Agency. Assessment report Vepacel A/H5N1 pre-pandemic influenza vaccine (whole virion, Vero cell derived, inactivated) [Procedure No. EMEA/ H/C/002089; online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Public-assessment-report/human/002089/WC500124225. pdf[Accessed 2012 Apr 10]
19. Ehrlich HJ, Muller M, Oh HML, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008 Jun 12; 358 (24): 2573-84 (Pubitemid 351831358)
20. Ehrlich HJ, Muller M, Fritsch S, et al. A cell culture (Vero)- derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009 Oct 1; 200 (7): 1113-8
21. Tambyah PA, Wilder-Smith A, Pavlova BG, et al. Safety and immunogenicity of two different doses of a Vero cellderived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 2012; 30 (2): 329-35
22. Van der Velden M, Geisberger A, Aichinger G, et al. Safety and immunogenicity of a whole virus, vero cell-derived H5N1 pandemic influenza vaccine in immunocompromised and chronically ill patients [poster]. 4th European Scientific Working Group on Influenza (ESWI) Conference; 2011 Sep 11-14; Malta
23. Fritz R, Sabarth N, Kiermayr S, et al. A vero cell-derived whole-virus H5N1 vaccine effectively induces neura- minidase-inhibiting antibodies. J Infect Dis 2012; 205 (1): 28-34
24. Crowe BA, Bruhl P, Gerencer M, et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 2010; 29 (2): 166-73
25. European Medicines Agency. Note for guidance on harmonization of requirements for influenza vaccines (CPMP/ BWP/214/96) [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500003945.pdf [Accessed 2012 Apr 10]
26. European Medicines Agency. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision). (EMEA/CPMP/ VEG/4717/03-Rev.1) [online]. Available from URL:http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/10/WC500003993. pdf [Accessed 2012 Apr 10]